Biocryst Pharmaceuticals (BCRX) Accounts Payables (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Accounts Payables came in at $11.0 million in Q1 2026, up 9.05% YoY from $10.0 million in Q1 2025, and down 30.76% on a QoQ basis from $15.8 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Accounts Payables (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Accounts Payables data on file, last reported at $11.0 million in Q1 2026.
- Quarterly Accounts Payables rose 9.05% year-over-year to $11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (up 9.05% YoY) and the FY2025 annual result came in at $15.8 million, up 35.92% from the prior year.
- Accounts Payables fell to $11.0 million in Q1 2026, from $15.8 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $20.9 million in Q4 2023 to a low of $5.6 million in Q3 2025.
- A 5-year average of $11.5 million and a median of $11.6 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables jumped 90.44% — and 2025, when it sank 58.71%.
- Tracing BCRX's Accounts Payables over 5 years: stood at $14.4 million in 2022, then soared by 45.53% to $20.9 million in 2023, then plunged by 44.27% to $11.6 million in 2024, then jumped by 35.92% to $15.8 million in 2025, then tumbled by 30.76% to $11.0 million in 2026.
- The last three Accounts Payables figures came in at $11.0 million (Q1 2026), $15.8 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 356.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.43 Bn | 2.08 Bn | 214.41 Mn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.46 Mn |
| Mar 31, 2026 | 10.96 Mn |
| Dec 31, 2025 | 15.83 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Jun 30, 2025 | 8.59 Mn |
| Mar 31, 2025 | 10.05 Mn |
| Dec 31, 2024 | 11.64 Mn |
| Sep 30, 2024 | 13.48 Mn |
| Jun 30, 2024 | 7.79 Mn |
| Mar 31, 2024 | 11.91 Mn |
| Dec 31, 2023 | 20.89 Mn |
| Sep 30, 2023 | 10.57 Mn |
| Jun 30, 2023 | 13.89 Mn |
| Mar 31, 2023 | 6.25 Mn |
| Dec 31, 2022 | 14.36 Mn |
| Sep 30, 2022 | 8.62 Mn |
| Jun 30, 2022 | 12.02 Mn |
| Mar 31, 2022 | 13.88 Mn |
| Dec 31, 2021 | 27.81 Mn |
| Sep 30, 2021 | 19.69 Mn |